ArticleJournal of cancer research and clinical oncology2023

Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.

Jizhuang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.